|
|
|
| Clinical efficacy and safety study of Misoprostol combined with Oxytocin in treatment of postpartum hemorrhage |
| FU Ye |
| Department of Obstetrics and Gynecology, Hainan West Central Hospital, Hainan Provoince, Danzhou 571700, China |
|
|
|
|
Abstract Objective To analyze the clinical efficacy and safety of Misoprostol combined with Oxytocin in the treatment of postpartum hemorrhage (PH). Methods A total of 80 PH patients who were admitted to the Department of Obstetrics and Gynecology of Hainan West Central Hospital from January 2019 to September 2021 were selected as the research subjects. They were divided into the control group and the observation group by the random number table method, with 40 patients in each group. The control group was given oxytocin treatment, and the observation group was given Misoprostol combined with Oxytocin treatment. The postpartum amount of blood loss, coagulation function indicators, oxidative stress indicators and total incidence of adverse reactions were compared between the two groups. Results The amounts of postpartum blood loss at 2 and 24 h after delivery in the observation group were less than those in the control group, and the differences were statistically significant (P＜0.05). After treatment, the thrombin time (TT) and activated partial thrombin time (APTT) in the observation group were shorter than those in the control group, and the differences were statistically significant (P＜0.05). After treatment, the serum lipid peroxide (LPO) of the observation group was lower than that of the control group, and the serum glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) in the observation group were higher than those in the control group, with statistically significant differences (P＜0.05). No significant difference was observed in the total incidence of adverse reactions between the two groups (P＞0.05). Conclusion Misoprostol combined with Oxytocin can effectively reduce the amount of blood loss in PH patients, improve coagulation function, and reduce oxidative stress response, with fewer adverse reactions.
|
|
|
|
|
|
|
|
|
